Scientific article

Evidence on the protective role of high-density lipoprotein (HDL) in HIV-infected individuals

Published inCurrent vascular pharmacology, vol. 13, no. 2, p. 167-172
Publication date2015

During the last decades, the improvements in the assessment and management of cardiovascular risk have been successful in the reduction of acute cardiovascular outcomes. Among different prevention and therapeutic strategies, treatments targeting HDL increase have been indicated as promising interventions from both basic research and clinical studies. Although this therapeutic approach still requires confirmatory findings from large clinical trials, emerging evidence indicates that it would be particularly useful in some patient categories characterized by accelerated atherosclerotic diseases. In this regard, HIV-infected patients (under antiretroviral treatment or not) have been recently indicated as an appropriate target population. The present review will discuss the promising role of HDL in HIV-related cardiovascular pathophysiology and update novelties from clinical studies targeting HDL increase in HIV patients.

Research group
Citation (ISO format)
CALMY, Alexandra, MONTECUCCO, Fabrizio, W JAMES, Richard. Evidence on the protective role of high-density lipoprotein (HDL) in HIV-infected individuals. In: Current vascular pharmacology, 2015, vol. 13, n° 2, p. 167–172. doi: 10.2174/1570161111999131203092322
ISSN of the journal1570-1611

Technical informations

Creation11/28/2013 10:38:00 AM
First validation11/28/2013 10:38:00 AM
Update time03/14/2023 9:14:01 PM
Status update03/14/2023 9:14:01 PM
Last indexation05/02/2024 3:12:00 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack